Related Experiment Video
Updated: Jul 28, 2025

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Exosomal circRNAs in cancer: Implications for therapy resistance and biomarkers
Zhengjun Lin1, Yuqiao Ji1, Jian Zhou2
1Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China; Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, People's Republic of China.
Abstract:
Despite the advances in cancer treatment in recent years, the development of resistance to cancer therapy remains the biggest hurdle towards curative cancer treatments. Therefore, investigating the molecular mechanisms underlying cancer therapy resistance is of paramount clinical importance. Circular RNAs (circRNAs), novel members of the noncoding RNA family, are endogenous biomolecules in eukaryotes characterized by a covalently closed loop structure with multiple biological functions. Significantly, circRNAs are abundant and stable in exosomes and can be packaged, secreted and transferred to targeted tumour cells, thereby modulating diverse hallmarks of cancer behaviours, such as proliferation, migration, and immune escape. Notably, a great number of exosomal circRNAs are abnormally expressed during cancer treatment and can mediate cancer therapy resistance through complex mechanisms; therefore, targeting exosomal circRNAs is a promising therapeutic method to reverse therapy resistance. This review aimed to elucidate the mechanisms underlying exosomal circRNAs controlling the resistance of cancer to common therapies, such as chemotherapy, targeted therapy, immunotherapy and radiotherapy, and we also discussed the therapeutic potential of exosomal circRNAs as clinical biomarkers and novel targets in cancer clinical management. We also discussed the prospects and challenges of targeting exosomal circRNAs as a novel therapeutic strategy for reversing cancer therapy resistance.
Insights
Circular RNAs (circRNAs) in exosomes are key drivers of cancer therapy resistance. Targeting these exosomal circRNAs offers a promising strategy to overcome treatment failure and improve cancer patient outcomes.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Cancer therapy resistance is a major obstacle to curative treatments.
- Circular RNAs (circRNAs) are stable, noncoding RNAs found in exosomes.
- Exosomal circRNAs can influence cancer progression and treatment response.
Purpose of the Study:
- To review the mechanisms by which exosomal circRNAs mediate resistance to various cancer therapies.
- To explore the therapeutic potential of exosomal circRNAs as biomarkers and drug targets.
- To discuss future prospects and challenges in targeting exosomal circRNAs for cancer treatment.
Main Methods:
- Literature review of studies on circRNAs, exosomes, and cancer therapy resistance.
- Analysis of molecular mechanisms of exosomal circRNA involvement in chemotherapy, targeted therapy, immunotherapy, and radiotherapy resistance.
- Synthesis of current research on the clinical applications of exosomal circRNAs.
Main Results:
- Abnormally expressed exosomal circRNAs are implicated in resistance to multiple cancer treatments.
- Exosomal circRNAs can be transferred between cancer cells, affecting their behavior.
- These molecules play roles in cancer proliferation, migration, and immune evasion.
Conclusions:
- Exosomal circRNAs represent a significant mechanism driving cancer therapy resistance.
- Targeting exosomal circRNAs is a potential strategy to reverse resistance and improve therapeutic efficacy.
- Further research is needed to fully harness exosomal circRNAs as biomarkers and therapeutic targets in oncology.
Related Concept Videos
Treatment Resistant Cancers
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

